|
|
|
| Diagnostic value of serum HE4 in early endometrial carcinoma |
| YANG Shuli MIAO Jinwei HE YUE LI Wei WU Yumei▲ |
| Department of Gynecologic Oncology, Bejing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China |
|
|
|
Abstract Objective To explore the diagnostic value of serum human epididymis protein 4 (HE4) in early endometrial carcinoma. Methods Thirty-six cases of stage Ⅰ endometrium carcinoma (endometrial carcinoma group), 19 cases of endometrium atypical hyperplasia (endometrium atypical hyperplasia group) and 45 cases of normal endometrium (normal endometrium group) from May to December 2014 in Bejing Obstetrics and Gynecology Hospital, Capital Medical University were selected, the levels of serum HE4 of patients in each group were detected by enzyme-linked immunosorbent assay (ELISA). The diagnostic value of serum HE4 levels were analyzed. Results The level of HE4 in endometrial carcinoma group [(65.01±40.54) pmol/L] was significantly higher than that in endometrium atypical hyperplasia group [(41.01±15.23) pmol/L] and the normal endometrium group [(40.03±19.03) pmol/L], the differences were statistically significant (P < 0.01). There was no statistically significant difference in serum level of HE4 between the endometrium atypical hyperplasia group and endometrium atypical hyperplasia group (P > 0.05). In endometrial carcinoma group, the levels of serum HE4 were different in patients with different Myometrial infiltration depth, degree of tissue differentiation and vascular clearance. The AUC under the ROC curve was 0.733, and according to the ROC curve the cut-off of HE4 was 46.25 pmol/L, the sensitivity of early diagnosis of endometrial cancer was 68.4%, the specificity was 76.6%. Conclusion The level of serum HE4 in Endometial carcinoma patients is significantly increased, it can be used as biological markers of early diagnosis of endometrial carcinoma, the serum level of HE4 may assist to predict and evaluate risk factors before operation.
|
|
|
|
|
|
[1] 谢幸，苟文丽.妇产科学[M].8版.北京：人民卫生出版社，2013：313-317
[2] 李芳，吴素慧.HE4与妇科肿瘤相关性的研究进展[J].国际妇产科学杂志，2017，44（4）：369-373.
[3] 丁金旺，周国明，王克义，等.HE4在子宫内膜癌中的表达及其临床意义[J].中国妇幼健康研究，2015，26（3）：471-473.
[4] Li X，Gao YP，Tan MZ，et al. Expression of HE4 in Endometrial Cancer and Its Clinical Significance [J]. Biomed Res Int，2015：437-468.
[5] 马丁，沈铿，崔恒.常见妇科恶性肿瘤诊治指南[M].5版.北京：人民卫生出版社，2016：50-51
[6] Kirchhoff C，Habben I，Ivell R，et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors [J]. Biol Reprod，1991，45（2）：350-357.
[7] Antonsen SL，Høgdall E，Christensen IJ，et al. HE4 andCA125 levels in the preoperative assessment of endometrial cancer patients：a prospective multicenter study （ENDOMET） [J]. Acta Obstet Gynecol Scand，2013，92（11）：1313-1322.
[8] 丁巍，李瑛，朱颖军.人附睾蛋白4在子宫内膜非典型增生患者中筛查子宫内膜癌的临床价值[J].国际妇产科学杂志，2016，43（2）：165-167.
[9] Moore RG，Miller CM，Bromn AK，et al. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus [J]. Int J Gynecol Cancer，2011，21（7）：1185-1190.
[10] Zanotti L，Bignotti E，Calza S，et al. Human epididymisprotein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome [J]. Clin Chen Lab Med，2012，50（12）：2189-2198.
[11] 张晶，王赞宏.人附睾蛋白4在子宫内膜癌中临床价值的评估[J].国际妇产科学杂志，2013，40（5）：440-442.
[12] Bignotti E，Ragnoli M，Zanotti L，et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients [J]. Br J Cancer，2011，104（9）：1418-1425.
[13] Urban N，Thorpe J，Karlan BY，et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer [J]. Cancer Epidemiol Biomarkers Prev，2012，21（11）：2087-2094.
[14] Hallamaa M，Suvitie P，Huhtinen K，et al. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women [J]. Gynecol Oncol，2012，125（3）：667-672.
[15] Angioli R，Plotti F，Capriglione S，et al. The role of novel biomarker HE4 in endometrial cancer：a case control prospective study [J]. Tumour Biol，2013，34（1）：571-576.
[16] Yιlmaz SA，Altιnkaya SÖ，Kerimoglu ÖS，et al. The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions [J]. J Obstet Gynaecol，2017，37（1）：58-63.
[17] 谢榕，曾玮，刘桐雨，等.附睾蛋白4在子宫内膜癌患者体内表达及临床诊断价值[J].中国临床实用医学，2014， 5（6）：22-24. |
|
|
|
